Articles

Time for a ‘brain dump’

Rounding up some recent neurological R&D stories
Written byJeffrey Bouley
| 4 min read

With our show preview of the annual meeting of the Society for Neuroscience this issue, it seemed appropriate to spend a little extra time here in the Research and Development section to do a roundup of several recent neurology-related stories that have come through the inbox, starting with Milan, Italy-based Axxam S.p.A, which in early September announced the start of a research collaboration with Sanofi designed to further optimize a number of lead series of small molecules targeted against a range of diseases of the central nervous system (CNS).

The program, initiated at Axxam via a high-throughput screen of the Axxam small-molecule screening library, yielded a number of tractable hit series. Subsequent multi-parameter optimization identified potent and selective molecules with high CNS exposures and showed promising results in disease-relevant pharmacology models.

Following an initial evaluation phase in-house, Sanofi and Axxam will continue the program under a joint research agreement with activities to be carried out at Axxam and Sanofi research facilities. If successful, Sanofi has an option to enter into a subsequent licensing agreement based on the research. The exact pharmacological target and financial terms of this agreement with Sanofi were not disclosed.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.